All sponsors

Jiangsu HengRui Medicine Co., Ltd. $600276.SS

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS72
PHASE 3 / 2-331
RECRUITING42
READOUTS ≤12 MONTHS28
READOUT SLIPPED >6 MO30%

Delay Index: of 46 active trials registered more than a year ago, 14 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open Jiangsu HengRui Medicine Co., Ltd. on the live radar map → 📅 $600276.SS readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
SHR-1316、Paclitaxel (Albumin Bound)、Carboplatin
NCT04316364
P3RecruitingNon-Small-Cell Lung Cancer5372023-04-15
Hetrombopag
NCT05864014
P3Active, not recruitingChemotherapy-Induced Thrombocytopenia2132025-03-03
HRS-9231
NCT06731829
P2Not yet recruitingFor Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions782025-04
camrelizumab; famitinib malate
NCT04906993
P3Active, not recruitingCervical Cancer4432025-06-10 (+29 mo)
Linperlisib ; Rituximab
NCT06981988
P1/2Not yet recruitingRelapsed/Refractory Indolent NHL802025-08
HRS-1167 tablets
NCT06689163
P1/2RecruitingProstate Cancer662025-11-30
HRS-4642
NCT06385678
P1/2Active, not recruitingAdvanced KRAS G12D Mutant Solid Tumors472025-12 (+2 mo)
HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab
NCT05945901
P2/3Active, not recruitingColorectal Cancer6692025-12-01
HRS-6213
NCT07070349
P1/2RecruitingPatients With Solid Tumors482026-01
SHR-3167
NCT07018453
P2Active, not recruitingType 2 Diabetes Mellitus1732026-02 (+2 mo)
SHR-A1811 Injection
NCT07051486
P2RecruitingRecurrent or Metastatic Cervical Cancer602026-02
SHR-A1811
NCT06430437
P3RecruitingNon-Small Cell Lung Cancer With HER2- Mutations3002026-02
RSS0393 Ointment
NCT07102888
P2Not yet recruitingPlaque Psoriasis in Children; Plaque Psoriasis in Adolescents202026-02
RSS0393 ointment
NCT06918743
P2Not yet recruitingPsoriatic Subjects1472026-03
SHR0302Base gel
NCT06790862
P2Active, not recruitingVitiligo1552026-03-03
SHR-A1811
NCT05814354
P3Active, not recruitingBreast Cancer5512026-03-20 (+14 mo)
HRS-6768
NCT06925581
P1/2RecruitingAdvanced Solid Tumors842026-04
camrelizumab
NCT04342910
P3RecruitingGastric Cancer5502026-04-01 (+48 mo)
SHR2554; Chidamide analog tablets
NCT06122389
P3RecruitingRelapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy1302026-05
SHR-A1904
NCT05277168
P1/2RecruitingAdvanced Solid Tumors832026-05 (+2 mo)
SHR-A1811 Injection
NCT06057610
P3Active, not recruitingHER2-PositiveRecurrent or Metastatic Breast Cancer8682026-07-15 (-15 mo)
TACE+Camrelizumab+Apatinib mesylate
NCT05320692
P3Active, not recruitingHepatocellular Carcinoma4232026-07-30 (+24 mo)
Camrelizumab
NCT04639180
P3Active, not recruitingHepatocellular Carcinoma (HCC)6872026-07-31 (+24 mo)
HRS-1738 Injection
NCT07056439
P1/2Not yet recruitingPET Imaging in Patients With Prostate Cancer502026-08
SHR6390
NCT04842617
P3Active, not recruitingHormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage,Female Breast Cancer52742026-10-31
SHR-A1811 combined with Pyrotinib.
NCT06015048
P1/2RecruitingHER2-expressing Advanced Solid Tumors3642026-11
Bupivacaine Liposome Injection
NCT06529432
P2RecruitingLocal Analgesia Via Nerve Block962026-11 (+1 mo)
SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316
NCT05482568
P1/2RecruitingAdvanced Non-small Cell Lung Cancer3242026-12 (+36 mo)
HRS-6209 Capsules
NCT06974929
P1/2RecruitingBreast Cancer802026-12 (+12 mo)
Lutetium (177Lu) Oxodotreotide Injection;long-acting Octreotide
NCT05884255
P3RecruitingAdvanced Gastroenteropancreatic Neuroendocrine Tumor2202026-12
HRS-5041 tablets
NCT06568094
P1/2RecruitingProstate Cancer1002026-12 (+15 mo)
SHR-3167 Injection
NCT07472725
P2Active, not recruitingDiabetes Mellitus, Type 21022026-12
NCT04957550
NCT04957550
P3Active, not recruitingPsoriatic Arthritis4182026-12-13 (+37 mo)
HRS-9190
NCT07746726
P3RecruitingNeuromuscular Blockade3202026-12-31
SHR-A1811
NCT05424835
P3Active, not recruitingHER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane3812026-12-31 (+24 mo)
SHR-A1811
NCT06413745
P2Active, not recruitingHER2 Expression / Amplification in Patients With Biliary Tract Cancer592026-12-31 (+16 mo)
Fuzuloparib , Abiraterone acetate and Prednisone
NCT04691804
P3Active, not recruitingMetastatic Castration-Resistant Prostate Cancer (mCRPC)4962026-12-31
FH-006 for Injection
NCT07136142
P1/2RecruitingMalignant Solid Tumor1502027-02
SHR0302 Tablets
NCT07251595
P2RecruitingNon-segmental Vitiligo1762027-03
HRS-4642
NCT06520488
P1/2RecruitingAdvanced Solid Tumors1182027-03
Rezvilutamide Tablets
NCT07241416
P3RecruitingMetastatic Hormone-sensitive Prostate Cancer (mHSPC)2062027-03
SHR2554
NCT06368167
P2Not yet recruitingFollicular Lymphoma1052027-04
SHR-A1811
NCT06828354
P3RecruitingOvarian Cancer3002027-05
Pyrotinib
NCT03980054
P3Active, not recruitingBreast Cancer21352027-06 (+58 mo)
SHR-9803
NCT06906731
P1/2Not yet recruitingAdvanced Solid Tumors272027-06
SHR-A1811
NCT06123494
P3RecruitingHER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma3602027-06-30
SHR4640 ;Febuxostat
NCT07362355
P2RecruitingPrimary Gout and Hyperuricemia3402027-07
HRS-4508 tablet
NCT07003321
P2RecruitingSolid Tumor1202027-09
SHR-3167 Injection
NCT07920939
P3Not yet recruitingType 2 Diabetes4502027-10
HRS-4508+ Capecitabine
NCT07140393
P1/2RecruitingSolid Tumor1202027-10
RSS0343 Tabella
NCT06775340
P2RecruitingAdolescent Asthma2522027-11 (+24 mo)
SHR-4394
NCT07407283
P1/2RecruitingProstate Cancer1002027-11
FH-006 ; SHR-1316 ; BP102 ; Cisplatin ; Carboplatin
NCT07241767
P2RecruitingLung Cancer2002027-11
FH-006
NCT06735144
P1/2RecruitingMalignant Solid Tumor2002027-12
SHR-A1811 for Injection
NCT07196774
P3Active, not recruitingEarly-stage or Locally Advanced HER2-positive Breast Cancer7402027-12
HRS-4357 injection
NCT07311694
P3RecruitingPSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer3702027-12
HRS-6209 in Combination with Fulvestrant
NCT06555068
P1/2RecruitingAdvanced Unresectable or Metastatic Breast Cancer; Advanced Solid Tumors5282027-12 (+24 mo)
HRS-4508 tablet
NCT07232849
P2RecruitingLung Cancer1002027-12
SHR2554 Tablets
NCT07102901
P2RecruitingAdvanced Gastric Cancer; Metastatic Gastric Cancer3512027-12
SHR-3167
NCT07913061
P3Not yet recruitingDiabetes Mellitus, Type 26802028-01
HORIZON-CRC221
NCT07796763
P2Not yet recruitingAdvanced Colorectal Cancer Expressing HER2482028-05-01
Trastuzumab Rezetecan for Injection
NCT07497386
P2RecruitingUnresectable Locally Recurrent Breast Cancer; Unresectable Locally Metastatic Breast Cancer1502028-06
SHR2554; SHR-A2102
NCT07175220
P2RecruitingLocally Advanced or Metastatic Non-small Cell Lung Cancer2002028-10
Irinotecan Hydrochloride Liposome Injection (II); Oxaliplatin; 5Fluorouracil; Calcium folinate
NCT07238283
P3RecruitingFirst-line Treatment of Metastatic Pancreatic Cancer6622028-10
HRS-8364 Tablet
NCT07446153
P1/2RecruitingSolid Tumor2822028-12
Hetrombopag Olamine
NCT07286032
P3RecruitingPatients With Chemotherapy-Induced Thrombocytopenia1502028-12
HS-20093 for Injection
NCT07230106
P2RecruitingProstate Cancer2182028-12
HRS-7172 + AG + SHR-1316
NCT07806058
P1/2RecruitingPancreatic Cancer1402028-12-31
HRS-4642 + AG
NCT07232875
P3RecruitingKRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting5882029-04
FH-006
NCT07790380
P3RecruitingLocally Advanced, Recurrent or Metastatic ESCC Patients Who Have Failed Prior PD-1/PD-L1 Inhibitors Combined With Platinum-based Chemotherapy4802029-06-30
SHR-A1811
NCT06126640
P3Active, not recruitingHER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy16152030-04
HRS-6209 + Letrozole
NCT07894328
P3Not yet recruitingBreast Cancer10502031-07-30